OASIS II: A phase 2 trial of potential treatment regimens in people with mantle cell lymphoma

A phase 2 trial testing ibrutinib, anti-CD20 antibody and venetoclax in people with untreated mantle cell lymphoma (MCL). 

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT04802590
 

Trial aim and background

The aim of this trial is to test new treatment regimens in people with newly diagnosed MCL. It is a multicentre phase 2 trial which aims to compare two different treatment regimens:

  • Ibrutinib plus anti-CD20 antibody
  • Ibrutinib plus anti-CD20 antibody and venetoclax

Ibrutinib and venetoclax will be given for a maximum of 2 years, CD20 antibody for 3.5 years.

A response will be measured at 6 months in both treatment arms.

Who can enter

People aged over 18 and under 80 with newly diagnosed and untreated MCL may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • The Christie Foundation Trust, Manchester
  • Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich
  • Oxford University Hospitals NHS Foundation Trust, Oxford
  • University Hospitals Plymouth NHS Trust, Plymouth
  • Royal Cornwall Hospital Trust, Truro

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT04802590

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.